Trial of 225Ac-DOTATATE (RYZ101) in Subjects With ER+, HER2-negative Unresectable or Metastatic Breast Cancer Expressing SSTRs.
A phase 1/2 trial of Actinium-225 DOTATATE in HR-positive / HER2-negative breast cancer, run by RayzeBio, Inc., active and no longer recruiting.
Overview
Trial of 225Ac-DOTATATE (RYZ101) in Subjects With ER+, HER2-negative Unresectable or Metastatic Breast Cancer Expressing SSTRs. is a phase 1/2 interventional study registered as NCT06590857 by RayzeBio, Inc., with 16 participants enrolled, started 2024-07-19 and due to reach its primary completion in 2028-10. Interventions recorded: RYZ101 and Standard of Care Endocrine Therapy.
Similar pages
not linked directly; found by shared links- TrialStudy of the Theranostic Pair RYZ811 (Diagnostic) and RYZ801 (Therapeutic) to Identify and Treat Subjects With GPC3+ (Glypican-3) Unresectable HCC
Shares RayzeBio (BMS) and the tag pipeline.
- TrialStudy Evaluating Dosimetry, Randomized Dose Optimization, Dose Escalation and Efficacy of Ac-225 Rosopatamab Tetraxetan in Participants With PSMA PET-Positive Castration-Resistant Prostate Cancer (CRPC)
Shares Actinium-225 and the tag pipeline.
- AgentAAA817
Shares Actinium-225 and the tag pipeline.
- AgentFPI-2265
Shares Actinium-225 and the tag pipeline.
- BottleneckClinical trial capacity for radioligand therapy
Shares RayzeBio (BMS), Actinium-225 DOTATATE, Actinium-225.
- IdeaRecover legacy radium-226 sources worldwide as the feedstock for actinium-225
Shares Actinium-225 DOTATATE, Actinium-225.
- CompanyBristol Myers Squibb
Shares Actinium-225 DOTATATE, Actinium-225.
- TrialACTION-1
Shares Actinium-225 DOTATATE, Actinium-225.